EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Krystal Biotech's enterprise value is $3,915.06 Mil.
Krystal Biotech's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $17.91 Mil. Therefore, Krystal Biotech's EV-to-EBITDA for today is 218.66.
The historical rank and industry rank for Krystal Biotech's EV-to-EBITDA or its related term are showing as below:
KRYS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -19.89 Med: 150.55 Max: 260.83
Current: 218.66
During the past 8 years, the highest EV-to-EBITDA of Krystal Biotech was 260.83. The lowest was -19.89. And the median was 150.55.
KRYS's EV-to-EBITDA is ranked worse than 97.45% of 470
companies
in the Biotechnology industry
Industry Median: 9.14
vs KRYS: 218.66
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Krystal Biotech EV-to-EBITDA Historical Data
The historical data trend for Krystal Biotech's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Krystal Biotech's EV-to-EBITDA
For the Biotechnology subindustry, Krystal Biotech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krystal Biotech's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Krystal Biotech's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Krystal Biotech's EV-to-EBITDA falls into.
Krystal Biotech's current Enterprise Value is $3,915.06 Mil.
Krystal Biotech's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $17.91 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Krystal Biotech's PE Ratio for today is calculated as:
Krystal Biotech's share price for today is $156.88.
Krystal Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.090.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Krystal Biotech's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Krystal Biotech (Krystal Biotech) Business Description
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on development of easy to use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KRYS has been successfully added to your 